Biocon Limited

Other

Nagaraj Govindappa

Kedarnath Nanjund Sastry

Maria Melina Soares

Sanjay Tiwari

Mukesh Babuappa Patale

Suma Sreenivas

Kedamath Nanjund Sastry

Komal N Kanojia

Kedernath Sastry

Harish Iyer

Sreesha Srinivasa

Partha Hazra

Nitesh Dave

Usha Bughani

Yogesh Basavaraju

Krishnamurthy Venkatesan

Gokul Jothiraman

Shivakumar Madenahalli Channabasappa

Sankar Periyasamy

Nandini Nataraj

Reshmi Nair

Srividya Divakar

Komal Kanojia

The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, to fusion molecules of Anti-EGFR1-TGFβRII, Anti-EGFR1-PD1 and Anti-CTLA4-PD1 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.

Fusion immunomodulatory proteins and methods for making same

The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.

Anti-EGFR1-PD1 targeted/immunomodulatory fusion protein

The present invention provides for a composition and a method for treating a subject afflicted with a cancer, wherein the composition comprises therapeutically effective amounts of: (a) an anti-Programmed Death-Ligand 1 (PD-L1) antibody and (b) a targeted/immunomodulatory fusion protein comprising at least one tumor targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.

Immunotherapy methods using anti-PD-L1 antibodies in combination with EGFR1 targeted-TGF-beta immunomodulatory fusion proteins

CTLA4/PD1 targeted/immunomodulatory fusion proteins

The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, to fusion molecules of Anti-EGFR1-TGF&#x3b2;RII, Anti-EGFR1-PD1 and Anti-CTLA4-PD1 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.

Epidermal growth factor receptor targeted/immunomodulatory fusion proteins and methods of use for them

Targeted/TGF-&#xdf;RII fusion proteins and methods for making same

The present disclosure relates to a process of identification and isolation of sorbitol dehydrogenase promoter from. Further, the present disclosure also relates to expression of heterologous proteins under the control of Sorbitol dehydrogenase promoter in

Nucleotide sequence and a process thereof

Method of treating cancer with an EGFR targeted immunomodulatory fusion protein

Anti-CTLA4 antibody-TGF-&#x3b2;RII targeted/immunomodulatory fusion proteins

The disclosure relates to a process of obtaining a fully folded two chain insulin glargine that require no further processing to make it functionally active. The present disclosure discloses a surprising effect of over expression of Kex2p intracellularly under the control of inducible FLD1 promoter in the hostto produce two chain functional glargine secreted directly in the medium. The schematic diagram of how the two chains are made inside the hostand secretes into the medium.

Process of expressing a fully folded functional two chain insulin glargine

Targeted/immunomodulatory fusion proteins and methods for making same

The present invention relates to novel Prolipase-Bovine trypsinogen (PLBTR) fusion proteins, the genes encoding them, and the production and uses thereof. More specifically, the present invention relates to methods of producing in optimal quantities PLBTR fusion proteins which comprise a heterologous polypeptide which is normally susceptible to autocatalytic activity. More particularly, the present invention relates to fusion proteins which comprise an heterologous polypeptide, such as a serine protease, fused to a lipase signal sequence, which can be expressed by recombinant host cells in desired amounts. The present invention further relates to polynucleotides encoding such fusion proteins, to expression vectors for expression of such fusion proteins, to host cells transformed with such polynucleotides/vectors, and to methods of generating such fusion proteins.

Fusion proteins and method of expression thereof

Targeted/immunomodulatory fusion proteins

Growing community of inventors

Karnataka, India

Nagaraj Govindappa